Maintain the network and governance structure (M1-M12)
• Regular consultation of SC members (at least 4 times per year) through emails and online meetings to discuss pending issues, the implementation of network activities and agree upon new membership applications.
• Organisation of two face-to-face SC meetings to discuss the development and implementation of activities and strategies and potential responses to new challenges and trends.
• The membership database will be maintained and updated with new members. This will enable the network to utilise the existing expertise and knowledge among C-EHRN members.

Ensure implementation of network activities and cooperation (M1-M12)
• The CNO is responsible for the coordination, development and implementation of C-EHRN activities, the collection and analysis of data and information and the dissemination and promotion of results various communication channels.
• The CNO ensures as well the financial and technical management of the network activities.
• The FP system will be maintained and updated with new contacts. This means as well, that additional national experts can be added to the FP system and database (if they support the FPs in collecting national data and information). Ongoing support will be provided to all FPs.
• Cooperation with network partners and national harm reduction networks will be continued, including regular information exchange.
• An external evaluator and a researcher will evaluate the C-EHRN activities and results, by also taking C-EHRN member and expert opinions into account.

Consolidate and maintain thematic expertise C-EHRN (M1-M12)
The three thematic expert groups (TEGs) on HCV, ODP and NDT will support our network activities in the related areas. Based on the specific expertise among our members, we will include and consult our members for specific activities in the area on monitoring, capacity building and advocacy. This will be ensured through online consultation and the organisation of webinars and meetings.

Ensure communication and promotion of C-EHRN activities and results (M1-M12)
The communication strategy will be updated by identifying relevant events and opportunities for dissemination and promotion. Communication and promotion activities include:
• the communication of C-EHRN activities and results to C-EHRN members, partners and other relevant stakeholders. Relevant tools in the promotion and communication are the C-EHRN website and the social media accounts (Facebook, twitter, Linked-In and Instagram). In addition, C-EHRN newsletters will be disseminated regularly (at least 12 x year) to promote C-EHRN topics and events.
• The participation to various conferences, meetings and events in 2021. A detailed list of conferences and events will be prepared, including the International Harm Reduction Conference and the Addiction Conference organised by the EMCDDA.

C-EHRN is involved in a number of initiatives and cooperation, which also contribute to the communication and dissemination tasks of the network. This includes:
• European Civil Society Forum on Drugs (part of the core group and coordinator of the related CSFD Project) and the CSF HIV, Hepatitis and TB
• Achieve Coalition for Hepatitis C elimination in Europe.
• Thematic Network ‘Nobody Left Outside – Improving access to healthcare for marginalised and underserved groups’ under the EU Health Policy Platform.
• European HIV/HCV testing week, by providing training and support towards HR organisations.
• Joint Health Housing Cluster of FEANTSA and provides advice and support towards health-related topics.
• Cooperation with EMCDDA, EHRA, EuroNPUD, ECDC, HRI, INHSU, WHO, UNODC, Vienna NGO Committee on Drugs, IDPC, ELPA, EATG, Pompidou Group.


The monitoring activities are an essential element within our network and build on the input of our FPs and scientific experts. Key operational objectives in 2021:

Evaluate the Monitoring Tool and the monitoring process (M1-M4)
C-EHRN will carry out an evaluation among FPs and the SEG. The main outcomes of the evaluation will be discussed with the SC and the SEG and shared as well with all C-EHRN members.
The evaluation will assess the feasibility of the monitoring process, the content and (national) relevance of the questionnaire, the structure and content of the Monitoring Report, the advocacy relevance, the support of C-EHRN during the monitoring process and the potential technical challenges and bottlenecks. Based on the findings of the evaluation, the Monitoring Tool and the guidelines will be adapted accordingly. This will be organised by the scientific lead of the monitoring activities, in close cooperation with the CNO and the SEG.

Organise a Webinar for FPs (M4)
C-EHRN will organise a webinar for FPs to share the main findings of the evaluation and present the adapted Monitoring Tool + guidelines. The webinar will offer the opportunity to discuss relevant questions and agree on additional support structures.

Implement the final Monitoring Tool (M4-M6)
The FPs will implement the Monitoring Tool, based on the adapted guidelines and a detailed timeline, indicating the different steps in the process. Close cooperation with other national experts is foreseen to safeguard sufficient thematic expertise. This process will be closely monitored by the CNO and the scientific lead.

Analyse and summarise the results (M7)
• FPs will send their input to the CNO and fill in an additional evaluation questionnaire afterwards. This will help to better understand potential problems in the monitoring process and to adjust the monitoring if needed.
• The results of the monitoring will be analysed and summarised. This task will be carried out by the scientific lead of the SEG.

Write and launch the Monitoring Report (M8-M11)
• Based on the analysis of data and information, the scientific lead will write the monitoring report, including all relevant information and findings. The C-EHRN coordination and the SEG will be involved in this process and provide input and support.
• The final Monitoring Report will be launched at the end of the 2021.


Maintain and update the online knowledge and training hub on drug use and harm reduction (M1-M12)
The online knowledge hub was launched in 2019 and includes a large number of resources in the area of harm reduction and drug use, covering the priority topics of C-EHRN and more: HCV and drug use, overdose prevention, naloxone distribution, drug consumption rooms, new drug trends, civil society involvement, advocacy, peer involvement, outreach, and related topics, such as homelessness, sex work, migration. The online knowledge hub will be maintained and updated regularly by a subcontracted IT expert. Network members and partners will be encouraged to share their work through this platform.
We will as well ensure a continued maintenance and update of the Covid-19 Resource Centre, if the situation requires ongoing activities in this area.

Address thematic priorities and other relevant topics (M1-M12)
As part of the FPA (2018-2021), C-EHRN has identified three thematic priorities: HCV, ODP and NDT. These priorities are specifically addressed in the three TEGs), which consist of C-EHRN members with proven expertise and knowledge in the respective areas.
The TEGs organise regular online meetings to discuss pending issues and advise C-EHRN in the development and the implementation of network activities. To synthesize relevant input from our experts, specific workplans and priorities will be prepared. Each TEG will
• Provide feedback and advice in regard to the monitoring
• Provide and share relevant resources and publications for the online knowledge hub
• Identify specific priorities and define activities for 2021
• Organise a thematic webinar to inform network members and other interested stakeholders on related developments
• Contribute to thematic papers and/or factsheets

HCV related priorities include
• Promotion of HR services as important element in the cascade of care
• Sharing of good practice examples for HCV testing, treatment and care in HR settings
• Support of enabling policy environments to reduce barriers in access to HCV testing, treatment and care

ODT related priorities include
• Promotion of Naloxone and Drug Consumption Rooms (DCRs) as effective intervention to save lives
• Maintenance and update of the website of the International Network of Drug Consumption Rooms (INDCR) – a network, which is hosted by C-EHRN.
• Organisation of a thematic expert meeting in the area of DCRs to address developments, challenges and good practice examples on European, national and local level

NDT related priorities include
• Organisation of regular online calls to monitor and assess new drug trends in various European countries and regions. This will allow up-to date monitoring and will support the monitoring activities of C-EHRN.
• Sharing and combining of relevant information from other related networks and projects.

Other relevant topics
C-EHRN is involved in different activities and projects. Specific attention will be given to:
• The cooperation with the EMCDDA: since many years, C-EHRN is part of expert groups of different EMCDDA initiatives and consultation mechanisms and EMCDDA is part of the scientific expert group/advisory board of our network. In 2021 our cooperation with the EMCDDA will focus on the following priorities:
• COVID-19 implications for PWUDs and service provider
• The EMCDDA European Response Guide stakeholder consultation
• Hepatitis C best practice sharing
• The EMCDDA Drug Related Death Initiative
• Organisation of an envisaged Drug Consumption Room expert meeting
• Civil Society Involvement: The network is member of the CSFD and coordinator of the related CSFD Project. Relevant activities of the CSFD will be linked to our network, including the organisation of a Civil Society Conference, which will be organised by the CSFD in autumn 2021.
• Integrated approaches and intersectional approaches: C-EHRN has coordinated different projects addressin


Update the advocacy strategy for 2021 (M1-M3)
Based on the work of 2018-2020 and the challenges in the area of HR, C-EHRN will update the advocacy strategy for 2021. The strategy includes the formulation of short policy messages and a strategy on how to put them into practice. The advocacy strategy will describe the role of and the cooperation with other European networks and partners. Furthermore, it will stipulate in which way the strategy will be implemented and on which occasions advocacy activities need to be carried out. The advocacy strategy will cover the C-EHRN thematical priorities and other relevant topics, such as
HCV, overdose prevention, new drug trends, civil society involvement and the need for an integrated and holistic HR response.

Organise and participate in EU policy –related groups and events (M1-M12)
C-EHRN will participate in relevant policy meetings and contribute to advocacy activities and events on national and European level. This includes:
• Participation in the European Civil Society Forum on Drugs. As core member of the CSFD and coordinator of the CSFD Project, C-EHRN contributes significantly to the development of EU Drug Policy.
• C-EHRN is part of the coordination team of the reformed Civil Society Forum on HIV, Hepatitis and TB which provides a platform for the exchange of knowledge and knowhow between civil society organisations, the European Commission and other relevant actors.
• C-EHRN is part of several European initiatives and advisory groups (e.g. Achieve Coalition, WHO Europe).
• C-EHRN is part of the Thematic Network ‘Nobody Left Outside – Improving access to healthcare for marginalised and underserved groups’ under the EU Health Policy Platform.
• C-EHRN cooperates closely with European networks and organisations, including FEANTSA, EHRA, EATG and others. In addition, the network is involved in various European projects, which address health- and drug-related topics, marginalised groups, and social inclusion.
• C-EHRN organises and contributes to different European events (as described in 1.4.) and will create additional impact at policy level.
• C-EHRN will actively contribute to the dissemination and promotion of activities in the field of drugs and harm reduction through the EU Health Policy Platform.

Development of policy briefings and recommendations
C-EHRN will develop a set of policy recommendations, briefings and factsheets, covering the three priority areas of C-EHRN and additional topics identified in the Advocacy Strategy.
